(-)-Epigallocatechin-3-gallate reverses the expression of various tumor-suppressor genes by inhibiting DNA methyltransferases and histone deacetylases in human cervical cancer cells
- PMID: 25682960
- DOI: 10.3892/or.2015.3802
(-)-Epigallocatechin-3-gallate reverses the expression of various tumor-suppressor genes by inhibiting DNA methyltransferases and histone deacetylases in human cervical cancer cells
Abstract
There has been increasing evidence that numerous bioactive dietary agents can hamper the process of carcinogenesis by targeting epigenetic alterations including DNA methylation. This therapeutic approach is considered as a significant goal for cancer therapy due to the reversible nature of epigenetic-mediated gene silencing and warrants further attention. One such dietary agent, green tea catechin, (-)-epigallocatechin-3-gallate (EGCG) has been shown to modulate many cancer-related pathways. Thus, the present study was designed to investigate the role of EGCG as an epigenetic modifier in HeLa cells. DNA methyltransferase (DNMT) and histone deacetylase (HDAC) inhibition assays were conducted, and the transcription levels of DNMT3B and HDAC1 were assessed by enzymatic activity assay and RT-PCR, respectively. Furthermore, we studied the binding interaction of EGCG with DNMT3B and HDAC1 by molecular modeling as well as promoter DNA methylation and expression of retinoic acid receptor-β (RARβ), cadherin 1 (CDH1) and death-associated protein kinase-1 (DAPK1) in EGCG-treated HeLa cells by RT-PCR and MS-PCR. In the present study, time-dependent EGCG-treated HeLa cells were found to have a significant reduction in the enzymatic activity of DNMT and HDAC. However, the expression of DNMT3B was significantly decreased in a time-dependent manner whereas there was no significant change in HDAC1 expression. Molecular modeling data also supported the EGCG-mediated DNMT3B and HDAC1 activity inhibition. Furthermore, time-dependent exposure to EGCG resulted in reactivation of known tumor-suppressor genes (TSGs) in HeLa cells due to marked changes in the methylation of the promoter regions of these genes. Overall, the present study suggests that EGCG may have a significant impact on the development of novel epigenetic-based therapy.
Similar articles
-
Tea polyphenol (-)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines.Cancer Res. 2003 Nov 15;63(22):7563-70. Cancer Res. 2003. PMID: 14633667
-
Genistein Induces Alterations of Epigenetic Modulatory Signatures in Human Cervical Cancer Cells.Anticancer Agents Med Chem. 2018;18(3):412-421. doi: 10.2174/1871520617666170918142114. Anticancer Agents Med Chem. 2018. PMID: 28925878
-
(-)-Epigallocatechin-3-gallate reactivates silenced tumor suppressor genes, Cip1/p21 and p16INK4a, by reducing DNA methylation and increasing histones acetylation in human skin cancer cells.Carcinogenesis. 2011 Apr;32(4):537-44. doi: 10.1093/carcin/bgq285. Epub 2011 Jan 5. Carcinogenesis. 2011. PMID: 21209038 Free PMC article.
-
Gene methylation in gastric cancer.Clin Chim Acta. 2013 Sep 23;424:53-65. doi: 10.1016/j.cca.2013.05.002. Epub 2013 May 10. Clin Chim Acta. 2013. PMID: 23669186 Review.
-
The Epigenetic Modification of Epigallocatechin Gallate (EGCG) on Cancer.Curr Drug Targets. 2020;21(11):1099-1104. doi: 10.2174/1389450121666200504080112. Curr Drug Targets. 2020. PMID: 32364072 Review.
Cited by
-
Anti-tumor Effects of Polyphenols via Targeting Cancer Driving Signaling Pathways: A Review.Indian J Clin Biochem. 2024 Oct;39(4):470-488. doi: 10.1007/s12291-024-01222-y. Epub 2024 May 2. Indian J Clin Biochem. 2024. PMID: 39346722 Review.
-
Dietary Impacts on Gestational Diabetes: Connection between Gut Microbiome and Epigenetic Mechanisms.Nutrients. 2022 Dec 10;14(24):5269. doi: 10.3390/nu14245269. Nutrients. 2022. PMID: 36558427 Free PMC article. Review.
-
In Vitro and In Silico Studies of the Molecular Interactions of Epigallocatechin-3-O-gallate (EGCG) with Proteins That Explain the Health Benefits of Green Tea.Molecules. 2018 May 28;23(6):1295. doi: 10.3390/molecules23061295. Molecules. 2018. PMID: 29843451 Free PMC article. Review.
-
Preclinical Pharmacological Activities of Epigallocatechin-3-gallate in Signaling Pathways: An Update on Cancer.Molecules. 2020 Jan 22;25(3):467. doi: 10.3390/molecules25030467. Molecules. 2020. PMID: 31979082 Free PMC article. Review.
-
Cancer research in the United Arab Emirates from birth to present: A bibliometric analysis.Heliyon. 2024 Mar 12;10(6):e27201. doi: 10.1016/j.heliyon.2024.e27201. eCollection 2024 Mar 30. Heliyon. 2024. PMID: 38545132 Free PMC article.